Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2018 252 B
EBIT 2018 -
Net income 2018 37 752 M
Finance 2018 134 B
Yield 2018 1,73%
Sales 2019 272 B
EBIT 2019 -
Net income 2019 44 870 M
Finance 2019 144 B
Yield 2019 1,79%
P/E ratio 2018 37,65
P/E ratio 2019 30,14
EV / Sales2018 5,79x
EV / Sales2019 5,33x
Capitalization 1 592 B
More Financials
Company
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of pharmaceutical and diagnostic reagents focusing on prescription pharmaceuticals.Its products include respiratory, digestive, urinary, chemotherapy, hormone, vitamins, and metabolic drugs.The company was founded by Ichibei... 
Sector
Pharmaceuticals
Calendar

- No events available -

More about the company
Surperformance© ratings of ONO PHARMACEUTICAL CO., LT
Trading Rating : Investor Rating :
More Ratings
Latest news on ONO PHARMACEUTICAL CO., LT
10/17 ONO PHARMACEUTICAL : Opdivo Alone or Combined with Yervoy Shows Encouraging Resp..
10/17 ONO PHARMACEUTICAL : U.S. Food and Drug Administration (FDA) Accepts Bristol-Mye..
10/13 KARYOPHARM THERAPEUTICS : and Ono Pharmaceutical inks deal to commercialize Seli..
10/13 KARYOPHARM THERAPEUTICS : and Ono Pharmaceutical Co. Ltd. Sign Exclusive License..
10/12 ONO PHARMACEUTICAL : Enters into Exclusive License Agreement with Karyopharm to ..
10/02 ONO PHARMACEUTICAL : Notice of Completion of Acquisition of Own Shares (90.8KB)
09/29 ONO PHARMACEUTICAL : and BMSKK Submit Supplemental Application for Opdivo® (Nivo..
09/28 BRISTOL MYERS SQUIBB : Japan Ministry of Health, Labor and Welfare Approves Opdi..
09/28 ONO PHARMACEUTICAL : and Seikagaku Announce Initiation of a Late-Stage Phase II ..
09/27 ONO PHARMACEUTICAL : Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives F..
More news
Sector news : Generic Pharmaceuticals
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19DJEuropean Corporate Roundup for Thursday
More sector news : Generic Pharmaceuticals
Latest Tweets
10/12Karyopharm and Ono Pharmaceutical inks deal to commercialize Selinexor and KP..
1
10/12$KPTI: Karyopharm Therapeutics signs license development and commercializing ..
1
10/12Karyopharm and Ono Pharmaceutical Co. Ltd. Sign Exclusive License Agreement t.. 
10/12BRIEF-Karyopharm and Ono Pharmaceutical sign exclusive license agreement to d.. 
10/02Ono Pharmaceutical Co., Ltd. $Japan $OPHLY Rating Increased to Buy at Citigro.. 
More tweets
Qtime:108
News from SeekingAlpha
10/03 Ono Pharmaceutical Needs To Reinvest Its Windfall
09/29 YOUR DAILY PHARMA SCOOP : Axovant's Promised Upside, Gilead's Whistleblower Trou..
06/22 Only Bristol Bucks Big Pharma's Drive For External Reliance
06/02 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 2, 2017
05/31 Array out-licenses binimetinib and encorafenib to Ono Pharma for Japan and So..
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Technical analysis trends ONO PHARMACEUTICAL CO., LT
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 2 743  JPY
Spread / Average Target 1,5%
EPS Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Shozo Matsuoka Executive Officer & Manager-Medical Affairs
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director, EVP & General Manager-Development
Isao Ono Director & Managing Executive Officer
Sector and Competitors